Barricaid is a proven technology that reduces reoperations for reherniations by 81% in a well-defined
patient population. Learn about the clinical efficacy and superiority RCT for Barricaid from Oscar Yeh, Chief
Operating Officer of Intrinsic Therapeutics, Inc in this webinar, recorded on 12/9/21. For full benefit/risk
information, please visit www.barricaid.com/instructions.
